Needlestick from a Patient with HBV, HCV, and Pending HIV Status
At 02:20 a night-shift RN sustains a hollow-bore needlestick while recapping a butterfly needle after drawing blood from a patient admitted with cellulitis and a history of injection drug use. The source patient's chart shows HBsAg positive, HBeAg negative, HBV DNA 12,000 IU/mL drawn 3 months ago, HCV antibody positive with HCV RNA 1,200,000 IU/mL, and an HIV-1/2 antigen/antibody test from admission that is still pending. The RN received a 3-dose HBV series 12 years ago and had an anti-HBs of 45 mIU/mL three months after the last dose; no titers since. She is 10 weeks pregnant, has no other known conditions, and asks whether she must stop working.
1. Walk through the post-exposure management for each of the three bloodborne pathogens.
Read the worked answer
Hepatitis B. The source is HBsAg positive with detectable DNA - infectious, though HBeAg-negative status means lower titer than an HBeAg-positive source. The RN is a documented vaccine responder (anti-HBs 45 mIU/mL after the series). CDC guidance treats a documented post-vaccination anti-HBs of 10 mIU/mL or greater as evidence of protection, so no HBIG or booster is strictly required. However, 12 years have elapsed and program policy varies. The defensible approach: draw a current anti-HBs urgently (results do not need to delay other steps). If 10 mIU/mL or greater, nothing further. If less than 10, give HBIG 0.06 mL/kg IM plus a vaccine booster (or restart the series). Hepatitis B vaccine and HBIG are both safe in pregnancy.
HIV. Source status is unknown, so this is the urgent decision. Expedite the source's HIV antigen/antibody test; if the source cannot be tested or is positive, start 3-drug PEP immediately - do not wait for results when the source has a risk history and the exposure is hollow-bore with visible blood. A standard regimen is tenofovir/emtricitabine plus dolutegravir (or raltegravir), started within hours (ideally under 24) and continued 28 days if the source is confirmed positive. These agents are considered acceptable in pregnancy; loop in obstetrics.
Hepatitis C. No PEP exists. Baseline HCV antibody with reflex RNA, then HCV RNA at 3 weeks (or antibody at 4 months). If seroconversion occurs, direct-acting antivirals achieve cure above 95%.
2. What follow-up testing schedule would you set, and what work restrictions apply?
Read the worked answer
Testing schedule (baseline plus):
- HIV: baseline, 6 weeks, 12 weeks, and 6 months with a 4th-generation antigen/antibody assay; add HIV RNA if an acute seroconversion syndrome occurs.
- HBV: baseline anti-HBs, anti-HBc, and HBsAg if not already known; repeat at 6 months only if the RN is not immune.
- HCV: baseline antibody/RNA, RNA at 3 weeks, antibody at 4 months.
- Baseline CBC and renal/hepatic function if HIV PEP is started; repeat at 2 weeks for toxicity.
Work restrictions: none are indicated for bloodborne pathogen exposure. HIV, HBV, and HCV are not transmitted by casual contact, and a needlestick does not restrict patient care. She continues working, including in her pregnant state - pregnancy is not a restriction either. If she develops an acute seroconversion illness with fever, she should be evaluated, but that is routine sick leave.
Confidentiality: the exposure evaluation belongs in a confidential occupational health record, not the personnel file or the unit's assignment sheet. The source patient must not be told the nurse's identity or health information; conversely, the nurse is entitled to the source's results needed to guide PEP, with appropriate consent rules under state law.
3. Beyond this individual, what system failures does this event point to, and what would you change?
Read the worked answer
The event itself: recapping a butterfly needle is a classic preventable mechanism. Safety-engineered butterfly devices with sliding shields exist and should be the only type stocked on units with high blood-draw volume, including at night when staffing is thin.
Contributing system factors to examine:
- Was a sharps container within arm's reach at the point of use, or was the nurse walking to a distant container?
- Is the needleless/safety device on formulary actually available on night shift, or is it locked in a supply room?
- Is the exposure reporting process usable at 02:20 - is there a 24/7 hotline, an on-call occupational health clinician, and immediate access to PEP starter packs in the ED?
- Did the nurse hesitate to report? Time to PEP matters, and delay is a system defect, not a personal one.
Program-level actions: audit sharp devices by unit, track exposure rates per 100 occupied beds and by device type, feed results to a sharps safety committee with purchasing authority, and re-educate using the actual device rather than generic slides. Verify that source testing happens automatically for exposures rather than requiring a separate physician order that can be lost overnight.
Report the event through the facility's surveillance system and, where required, to the state; aggregate for trend analysis rather than treating it as a single incident.